New York Stock Exchange News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 921,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "273939b4-d667-4efa-bf81-c39365ffd9bf",
"title": "What's Driving Futu Holdings Ltd's Surprising 23% Stock Rally?",
"description": "Futu Holdings Ltd (FUTU), a burgeoning player in the capital markets industry, has experienced a notable fluctuation in its stock price recently. With a current",
"keywords": "GuruFocus, Article, News, GuruFocus Research, FUTU, MKTX, IBKR, HLI",
"snippet": "Futu Holdings Ltd (FUTU, Financial), a burgeoning player in the capital markets industry, has experienced a notable fluctuation in its stock price recently. Wit...",
"url": "https://www.gurufocus.com/news/2415656/whats-driving-futu-holdings-ltds-surprising-23-stock-rally",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-04-23T15:12:30.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "HLI",
"name": "Houlihan Lokey, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 38.409756,
"sentiment_score": 0.4404,
"highlights": [
{
"highlight": "MarketAxess Holdings Inc (MKTX, Financial) has a market cap of $7.71 billion, Interactive Brokers Group Inc (IBKR, Financial) boasts a $12.1 billion market cap, and <em>Houlihan</em> <em>Lokey</em> <em>Inc</em> (HLI, Financial) is valued at $8.89 billion.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "645dc009-42e7-4871-9dd3-16190763cdd5",
"title": "Understanding iQIYI Inc's Stock Dynamics: A Comprehensive Analysis",
"description": "iQIYI Inc (IQ), a prominent player in the media-diversified industry, has experienced a notable fluctuation in its stock price recently. With a current market c",
"keywords": "GuruFocus, Article, News, GuruFocus Research, IQ, NXST, MSGS, MANU",
"snippet": "iQIYI Inc (IQ, Financial), a prominent player in the media-diversified industry, has experienced a notable fluctuation in its stock price recently. With a curre...",
"url": "https://www.gurufocus.com/news/2415654/understanding-iqiyi-incs-stock-dynamics-a-comprehensive-analysis",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-04-23T15:12:20.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "MSGS",
"name": "Madison Square Garden Sports Corp.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 39.235374,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "Competitive Landscape\n\niQIYI operates in a competitive landscape, with key players such as Nexstar Media Group Inc (NXST, Financial) with a market cap of $5.44 billion, <em>Madison</em> <em>Square</em> <em>Garden</em> <em>Sports</em> <em>Corp</em> (MSGS, Financial) at $4.42 billion, and Manchester United PLC (MANU, Financial) at $2.63 billion.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MANU",
"name": "Manchester United plc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 19.080679,
"sentiment_score": 0.34,
"highlights": [
{
"highlight": "Competitive Landscape\n\niQIYI operates in a competitive landscape, with key players such as Nexstar Media Group Inc (NXST, Financial) with a market cap of $5.44 billion, Madison Square Garden Sports Corp (MSGS, Financial) at $4.42 billion, and <em>Manchester</em> <em>United</em> <em>PLC</em> (MANU, Financial) at $2.63 billion.",
"sentiment": 0.34,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "1e641e99-aeb6-49b0-9b61-e8fa060b3ace",
"title": "AptarGroup Inc's Dividend Analysis",
"description": "Understanding AptarGroup Inc's Dividend Sustainability and Growth AptarGroup Inc (ATR) recently announced a dividend of $0.41 per share, payable on 2024-05-16,",
"keywords": "GuruFocus, Article, News, GuruFocus Research, ATR",
"snippet": "Understanding AptarGroup Inc's Dividend Sustainability and Growth\n\nAptarGroup Inc (ATR, Financial) recently announced a dividend of $0.41 per share, payable on ...",
"url": "https://www.gurufocus.com/news/2415255/aptargroup-incs-dividend-analysis",
"image_url": "https://static.gurufocus.com/logos/0C00000ADR.png?12",
"language": "en",
"published_at": "2024-04-23T11:04:52.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "ATR",
"name": "AptarGroup, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 77.85768,
"sentiment_score": 0.4962,
"highlights": [
{
"highlight": "Understanding <em>AptarGroup</em> Inc's Dividend Sustainability and Growth\n\n<em>AptarGroup</em> <em>Inc</em> (ATR, Financial) recently announced a dividend of $0.41 per share, payable on 2024-05-16, with the ex-dividend date set for 2024-04-24.",
"sentiment": 0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "Using the data from GuruFocus, let's look into <em>AptarGroup</em> Inc's dividend performance and assess its sustainability.\n\nWhat Does <em>AptarGroup</em> <em>Inc</em> Do?",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "A Glimpse at <em>AptarGroup</em> Inc's Dividend History\n\n<em>AptarGroup</em> <em>Inc</em> has maintained a consistent dividend payment record since 1993. Dividends are currently distributed on a quarterly basis.\n\n<em>AptarGroup</em> <em>Inc</em> has increased its dividend each year since 1993, earning it the prestigious title of a dividend aristocrat.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Breaking Down <em>AptarGroup</em> Inc's Dividend Yield and Growth\n\nAs of today, <em>AptarGroup</em> <em>Inc</em> currently has a 12-month trailing dividend yield of 1.16% and a 12-month forward dividend yield of 1.18%, suggesting an expectation of increased dividend payments over the next 12 months.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "Over the past three years, <em>AptarGroup</em> Inc's annual dividend growth rate was 3.10%. Extended to a five-year horizon, this rate increased to 3.30% per year. And over the past decade, <em>AptarGroup</em> Inc's annual dividends per share growth rate stands at 4.50%.",
"sentiment": 0.7506,
"highlighted_in": "main_text"
},
{
"highlight": "Based on <em>AptarGroup</em> Inc's dividend yield and five-year growth rate, the 5-year yield on cost of <em>AptarGroup</em> <em>Inc</em> stock as of today is approximately 1.36%.\n\nThe Sustainability Question: Payout Ratio and Profitability\n\nTo assess the sustainability of the dividend, one needs to evaluate the company's payout ratio.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "As of 2023-12-31, <em>AptarGroup</em> Inc's dividend payout ratio is 0.33, indicating a balance between returning value to shareholders and retaining earnings for growth.\n\n<em>AptarGroup</em> Inc's profitability rank of 8 out of 10 as of 2023-12-31 suggests good profitability prospects.",
"sentiment": 0.9062,
"highlighted_in": "main_text"
},
{
"highlight": "Concluding Thoughts on <em>AptarGroup</em> Inc's Dividend Profile\n\nConsidering <em>AptarGroup</em> Inc's consistent dividend increases, a reasonable payout ratio, and a solid profitability rank, the company's dividend appears sustainable.",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "With a careful balance between yield and growth, <em>AptarGroup</em> <em>Inc</em> may continue to be a stable dividend-paying investment, but it is essential to keep an eye on the company's ability to adapt and grow in a competitive market.",
"sentiment": 0.7717,
"highlighted_in": "main_text"
},
{
"highlight": "GuruFocus Premium users can screen for high-dividend yield stocks using the High Dividend Yield Screener to find opportunities like <em>AptarGroup</em> <em>Inc</em>.\n\nThis article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AptarGroup</em> Inc's Dividend Analysis",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "e6549c6e-4114-47ee-8a9c-581aac1598b1",
"title": "NVR Inc (NVR) Surpasses Analyst Expectations with Strong Q1 Earnings",
"description": "Net Income: $394.3M for Q1 2024, up 14% year-over-year, surpassing estimates of $345.6M.Earnings Per Share: $116.41, an increase of 17% from Q1 2023, exceeding",
"keywords": "GuruFocus, Article, News, GuruFocus Research, NVR",
"snippet": "NVR Inc (NVR, Financial), a prominent player in the U.S. homebuilding and mortgage banking sectors, reported a notable increase in its first-quarter earnings, s...",
"url": "https://www.gurufocus.com/news/2415651/nvr-inc-nvr-surpasses-analyst-expectations-with-strong-q1-earnings",
"image_url": "https://static.gurufocus.com/logos/0C00000BXP.png?5",
"language": "en",
"published_at": "2024-04-23T15:11:37.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "NVR",
"name": "NVR, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 104.33807,
"sentiment_score": 0.409257,
"highlights": [
{
"highlight": "<em>NVR</em> <em>Inc</em> (<em>NVR</em>, Financial), a prominent player in the U.S. homebuilding and mortgage banking sectors, reported a notable increase in its first-quarter earnings, surpassing analyst expectations. The company announced its financial results on April 23, 2024, through its 8-K filing.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "Company Overview\n\n<em>NVR</em> <em>Inc</em> operates under three brands: Ryan Homes, NVHomes, and Heartland Homes, covering a broad geographic area in the United States including the Mid-Atlantic, North East, Mid-East, and South East. Besides homebuilding, <em>NVR</em> also engages in mortgage banking and title services, enhancing its market footprint and revenue streams.",
"sentiment": 0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "Challenges and Market Conditions\n\nDespite the positive revenue and income figures, <em>NVR</em> experienced a slight decrease in its gross profit margin in the homebuilding segment, which dipped to 24.5% from 24.6% in Q1 2023. Additionally, the average settlement price saw a 2% decrease.",
"sentiment": -0.1684,
"highlighted_in": "main_text"
},
{
"highlight": "Analysis and Outlook\n\nThe first quarter results of <em>NVR</em> <em>Inc</em> reflect a resilient business model and effective market strategies that have allowed the company to outperform analyst expectations and navigate challenging market conditions.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "Conclusion\n\n<em>NVR</em> Inc's performance in the first quarter of 2024 positions it as a strong contender in the homebuilding and mortgage banking industry. With strategic operations and a solid financial base, <em>NVR</em> is well-equipped to capitalize on market opportunities and navigate potential challenges in the upcoming quarters.",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "Explore the complete 8-K earnings release (here) from <em>NVR</em> <em>Inc</em> for further details.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>NVR</em> <em>Inc</em> (<em>NVR</em>) Surpasses Analyst Expectations with Strong Q1 Earnings",
"sentiment": 0.5106,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "5f8697d9-94a1-4d91-8c94-765efd35a4a0",
"title": "La FTC bloque le projet de rachat de Capri par Tapestry",
"description": "La Federal Trade Commission (FTC) a intenté une action en justice pour bloquer l'acquisition de Capri Holdings Limited par Tapestry, Inc. pour un mont - 23/04/2024 14:54",
"keywords": "",
"snippet": "(AOF) - La Federal Trade Commission (FTC) a intenté une action en justice pour bloquer l'acquisition de Capri Holdings Limited par Tapestry, Inc. pour un monta...",
"url": "https://www.abcbourse.com/marches/la-ftc-bloque-le-projet-de-rachat-de-capri-par-tapestry_628561",
"image_url": "https://www.abcbourse.com/apple-icon.png",
"language": "fr",
"published_at": "2024-04-23T14:54:00.000000Z",
"source": "abcbourse.com",
"relevance_score": null,
"entities": [
{
"symbol": "CPRI",
"name": "Capri Holdings Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 41.19989,
"sentiment_score": null,
"highlights": [
{
"highlight": "(AOF) - La Federal Trade Commission (FTC) a intenté une action en justice pour bloquer l'acquisition de <em>Capri</em> <em>Holdings</em> <em>Limited</em> par Tapestry, Inc. pour un montant de 8,5 milliards de dollars. Cette opération vise à combiner trois concurrents proches : les marques Coach et Kate Spade de Tapestry et la marque Michael Kors de Capri.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "\"<em>Capri</em> <em>Holdings</em> est en profond désaccord avec la décision de la FTC. Les réalités du marché, que la contestation du gouvernement ignore, démontrent de manière écrasante que cette transaction ne limitera pas, ne réduira pas ou ne restreindra pas la concurrence\", peut-on lire dans cette déclaration.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TPR",
"name": "Tapestry, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 48.757774,
"sentiment_score": null,
"highlights": [
{
"highlight": "(AOF) - La Federal Trade Commission (FTC) a intenté une action en justice pour bloquer l'acquisition de Capri Holdings Limited par <em>Tapestry</em>, <em>Inc</em>. pour un montant de 8,5 milliards de dollars. Cette opération vise à combiner trois concurrents proches : les marques Coach et Kate Spade de <em>Tapestry</em> et la marque Michael Kors de Capri.",
"sentiment": 0.0422,
"highlighted_in": "main_text"
},
{
"highlight": "Capri dit vouloir \"défendre vigoureusement cette affaire devant les tribunaux aux côtés de <em>Tapestry</em> et de mener à bien l'acquisition en cours\".\n\n\n\n\"La FTC américaine est la seule autorité de régulation à ne pas avoir approuvé cette transaction, qui a reçu les approbations requises de toutes les autres juridictions\", précise, en outre, Capri.",
"sentiment": 0.0422,
"highlighted_in": "main_text"
},
{
"highlight": "La FTC bloque le projet de rachat de Capri par <em>Tapestry</em>",
"sentiment": 0.0422,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "81271eec-de87-46fe-9d70-b63d416e36cb",
"title": "Here’s What To Expect From Corning’s Q1",
"description": "We expect the company’s revenues to come in at $3.1 billion and adjusted earnings of $0.35 per share, aligning with the consensus estimates.",
"keywords": "Q1, GLW, Corning Stock, S&P 500, glw stock, glw revenue, glw q1, glw valuation, corning",
"snippet": "UKRAINE - 2021/10/09: In this photo illustration Corning Incorporated logo seen displayed on a ... [+] smartphone and in the background. (Photo Illustration by ...",
"url": "https://www.forbes.com/sites/greatspeculations/2024/04/23/heres-what-to-expect-from-cornings-q1/",
"image_url": "https://imageio.forbes.com/specials-images/imageserve/61f0126db77f2c141a46d1ec/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
"language": "en",
"published_at": "2024-04-23T14:30:13.000000Z",
"source": "forbes.com",
"relevance_score": null,
"entities": [
{
"symbol": "GLW",
"name": "Corning Incorporated",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 40.974163,
"sentiment_score": 0,
"highlights": [
{
"highlight": "UKRAINE - 2021/10/09: In this photo illustration <em>Corning</em> <em>Incorporated</em> logo seen displayed on a ... [+] smartphone and in the background. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images\n\nCorning Stock (<em>NYSE</em>: <em>GLW</em>) will report its Q1 2024 results on Tuesday, April 30.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "ac4085df-8f0b-48db-9378-c6172c6c8f6e",
"title": "Should You Pick Alaska Airlines Stock At $45 After Q1 Beat?",
"description": "The company reported revenue of $2.23 billion and an adjusted loss per share of $0.92, compared to the consensus estimates of $2.18 billion in sales and loss per share...",
"keywords": "Alaska Air, S&P 500, HQ Portfolio, alk stock, alk revenue, alk q1, alk valuation",
"snippet": "SAN FRANCISCO, UNITED STATES - APRIL 22: Alaska Airlines planes takeoff and land at San Francisco ... [+] International Airport (SFO) in San Francisco, Californ...",
"url": "https://www.forbes.com/sites/greatspeculations/2024/04/23/should-you-pick-alaska-airlines-stock-at-45-after-q1-beat/",
"image_url": "https://imageio.forbes.com/specials-images/imageserve/66278a867f7328ff1d97ca86/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
"language": "en",
"published_at": "2024-04-23T13:45:09.000000Z",
"source": "forbes.com",
"relevance_score": null,
"entities": [
{
"symbol": "^GSPC",
"name": "S&P 500",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "index",
"industry": "N/A",
"match_score": 30.944794,
"sentiment_score": -0.178025,
"highlights": [
{
"highlight": "Firstly, looking at its stock performance, ALK stock has seen little change, moving slightly from levels of $50 in early January 2021 to around $45 now, vs. an increase of about 30% for the <em>S</em>&<em>P</em> <em>500</em> over this roughly three-year period. ALK has had a poor run, with the stock losing value in each of the last 3 years.",
"sentiment": -0.25,
"highlighted_in": "main_text"
},
{
"highlight": "In comparison, returns for the <em>S</em>&<em>P</em> <em>500</em> have been 27% in 2021, -19% in 2022, and 24% in 2023 — indicating that ALK underperformed the S&P in 2021 and 2023.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "In fact, consistently beating the <em>S</em>&<em>P</em> <em>500</em> — in good times and bad — has been difficult over recent years for individual stocks; for heavyweights in the Industrials sector including CAT, GE, and UNP, and even for the megacap stars GOOG, TSLA, and MSFT.",
"sentiment": -0.7269,
"highlighted_in": "main_text"
},
{
"highlight": "In contrast, the Trefis High Quality Portfolio, with a collection of 30 stocks, has outperformed the <em>S</em>&<em>P</em> <em>500</em> each year over the same period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.",
"sentiment": 0.2648,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ALK",
"name": "Alaska Air Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 31.842342,
"sentiment_score": 0.171567,
"highlights": [
{
"highlight": "(Photo by Tayfun Coskun/Anadolu via Getty Images) Anadolu via Getty Images\n\n<em>Alaska</em> <em>Air</em> (<em>NYSE</em>: <em>ALK</em>) recently reported its Q1 results, with top line and bottom line exceeding the street estimates.",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "There was an incident in which the cabin side panel detached midair on <em>Alaska</em> <em>Air</em> (Boeing 737 Max 9) flight 1282 on January 9, 2024. Following the incident, the Federal Aviation Administration grounded Boeing 737 Max 9 aircraft. The company inspected its fleet and the aircraft returned to service in February.",
"sentiment": -0.128,
"highlighted_in": "main_text"
},
{
"highlight": "It should be noted that Boeing paid $162 million to <em>Alaska</em> <em>Air</em> in initial cash compensation for the financial impact on <em>Alaska</em> <em>Air</em> due to the grounding of Boeing’s 737 MAX airplanes.\n\nOverall, Alaska’s performance in Q1 was better than expectations, and it has raised its earnings outlook for the full-year.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "3f7501ea-f21d-4ec4-805f-14645728634b",
"title": "Rising 25% Year To Date, Will Q1 Results Drive Chipotle Stock Higher?",
"description": "We expect CMG’s stock to trade lower with revenues and earnings missing the expectations marginally in its first-quarter results.",
"keywords": "Chipotle, Chipotle Mexican Grill, NYSE, S&P 500, cmg stock, cmg revenue",
"snippet": "NEW YORK, NEW YORK - FEBRUARY 06: A Chipolte restaurant stands in Manhattan on February 06, 2024 in ... [+] New York City. Chipotle Mexican Grill (CMG) reports ...",
"url": "https://www.forbes.com/sites/greatspeculations/2024/04/23/rising-25-year-to-date-will-q1-results-drive-chipotle-stock-higher/",
"image_url": "https://imageio.forbes.com/specials-images/imageserve/662789efc62c887c122b6935/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
"language": "en",
"published_at": "2024-04-23T13:00:45.000000Z",
"source": "forbes.com",
"relevance_score": null,
"entities": [
{
"symbol": "FRGAP",
"name": "Franchise Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 7.239506,
"sentiment_score": 0.7906,
"highlights": [
{
"highlight": "It also signed its first-ever <em>franchise</em> agreement with a Middle Eastern operator to open stores in Dubai and Kuwait. The international expansion will probably continue for a long time if its concept is successful with other cultures.",
"sentiment": 0.7906,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "^GSPC",
"name": "S&P 500",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "index",
"industry": "N/A",
"match_score": 27.985355,
"sentiment_score": 0.10205,
"highlights": [
{
"highlight": "CMG stock has seen extremely strong gains of 105% from levels of $1385 in early January 2021 to around $2870 now, vs. an increase of about 30% for the <em>S</em>&<em>P</em> <em>500</em> over this roughly 3-year period. However, the increase in CMG stock has been far from consistent. Returns for the stock were 26% in 2021, -21% in 2022, and 65% in 2023.",
"sentiment": 0.8703,
"highlighted_in": "main_text"
},
{
"highlight": "In comparison, returns for the <em>S</em>&<em>P</em> <em>500</em> have been 27% in 2021, -19% in 2022, and 24% in 2023 - indicating that CMG underperformed the S&P in 2021 and 2022.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "In fact, consistently beating the <em>S</em>&<em>P</em> <em>500</em> - in good times and bad - has been difficult over recent years for individual stocks; for heavyweights in the Consumer Discretionary sector including AMZN, TSLA, and TM, and even for the megacap stars GOOG, MSFT, and AAPL.",
"sentiment": -0.7269,
"highlighted_in": "main_text"
},
{
"highlight": "In contrast, the Trefis High Quality Portfolio, with a collection of 30 stocks, has outperformed the <em>S</em>&<em>P</em> <em>500</em> each year over the same period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride as evident in HQ Portfolio performance metrics.",
"sentiment": 0.2648,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "SBUX",
"name": "Starbucks Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 16.852058,
"sentiment_score": 0.6249,
"highlights": [
{
"highlight": "That compares to a P/E ratio of 24x P/E ratio for McDonald’s (NYSE: MCD) and 23x for <em>Starbucks</em> (<em>NASDAQ</em>: <em>SBUX</em>). CMG stock has experienced an enormous surge since its bottom in October 2023 and has yet to experience any meaningful retracement.\n\nIt is helpful to see how its peers stack up.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CMG",
"name": "Chipotle Mexican Grill, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 36.806202,
"sentiment_score": 0.1591,
"highlights": [
{
"highlight": "<em>Chipotle</em> <em>Mexican</em> <em>Grill</em> (CMG) reports Q4 and full-year results late Tuesday.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(Photo by Spencer Platt/Getty Images) Getty Images\n\n<em>Chipotle</em> <em>Mexican</em> <em>Grill</em> stock (<em>NYSE</em>: <em>CMG</em>), a fast-casual restaurant chain that focuses on fresh and organic ingredients in burritos, salads, and more, is scheduled to report its fiscal first-quarter results on Wednesday, April 24.",
"sentiment": 0.3182,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "6fbafab3-bd88-4fe0-9578-6835138a800d",
"title": "What Should You Do With Caterpillar Stock Ahead Of Q1?",
"description": "Although we expect Caterpillar to post an upbeat Q1, we believe its stock is fully valued at its current levels of under $355.",
"keywords": "Caterpillar, S&P 500, cat stock, cat revenue, cat q1, cat valuation",
"snippet": "Colin Mitchell, in driver's seat, a senior associate of testing and validation, lifts the bucket on ... [+] the 980 XE medium wheel loader on Wednesday, March 2...",
"url": "https://www.forbes.com/sites/greatspeculations/2024/04/23/what-should-you-do-with-caterpillar-stock-ahead-of-q1/",
"image_url": "https://imageio.forbes.com/specials-images/imageserve/6627888e40158b603dc6aab7/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
"language": "en",
"published_at": "2024-04-23T11:30:30.000000Z",
"source": "forbes.com",
"relevance_score": null,
"entities": [
{
"symbol": "CAT",
"name": "Caterpillar Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 46.573265,
"sentiment_score": 0.425933,
"highlights": [
{
"highlight": ". [+] the 980 XE medium wheel loader on Wednesday, March 27, 2024, at the <em>Caterpillar</em> Proving Grounds in Washington, Illinois. (Vincent Alban/Chicago Tribune/Tribune News Service via Getty Images) TNS\n\n<em>Caterpillar</em> (<em>NYSE</em>: <em>CAT</em>) will report its Q1 2024 results on Thursday, April 25.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Although we expect <em>Caterpillar</em> <em>Caterpillar</em> to post an upbeat Q1, we believe its stock is fully valued at its current levels of under $355. Our interactive dashboard analysis of Caterpillar’s Earnings Preview has more details on how the company’s revenues and earnings will likely trend for the quarter.",
"sentiment": 0.4877,
"highlighted_in": "main_text"
},
{
"highlight": "From a valuation perspective, we think <em>Caterpillar</em> is fully priced. We estimate Caterpillar’s valuation to be $315 per share, roughly 10% below its current price of $355. At its current levels, CAT stock is trading at a little over 16x its forward estimated earnings of $21.72 in 2024.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Coming to the latest quarter, although an improvement in overall pricing should help <em>Caterpillar</em>, it expects a lower dealer inventory level compared to the prior-year quarter, likely weighing on the overall sales growth. The company expects its expenses to increase in the first quarter, likely resulting in a slight decline in operating margin.",
"sentiment": 0.8126,
"highlighted_in": "main_text"
},
{
"highlight": "Overall, 2024 is expected to be a year of tepid growth for <em>Caterpillar</em> and unless the company surprises with a strong earnings beat, better margin, or guidance, we don’t expect any significant growth in its stock in the near term.\n\nWhile CAT stock appears fully valued, it is helpful to see how Caterpillar’s Peers fare on metrics that matter.",
"sentiment": 0.9593,
"highlighted_in": "main_text"
},
{
"highlight": "What Should You Do With <em>Caterpillar</em> Stock Ahead Of Q1?",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "^GSPC",
"name": "S&P 500",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "index",
"industry": "N/A",
"match_score": 31.617811,
"sentiment_score": 0.0894,
"highlights": [
{
"highlight": "CAT stock has seen extremely strong gains of 95% from levels of $180 in early January 2021 to around $355 now, vs. an increase of about 30% for the <em>S</em>&<em>P</em> <em>500</em> over this roughly three-year period.",
"sentiment": 0.8197,
"highlighted_in": "main_text"
},
{
"highlight": "In comparison, returns for the <em>S</em>&<em>P</em> <em>500</em> have been 27% in 2021, -19% in 2022, and 24% in 2023 — indicating that CAT underperformed the S&P in 2021 and 2023.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "In fact, consistently beating the <em>S</em>&<em>P</em> <em>500</em> — in good times and bad — has been difficult over recent years for individual stocks; for other heavyweights in the Industrials sector, including GE, UNP, and RTX, and even for the megacap stars GOOG, TSLA, and MSFT.",
"sentiment": -0.7269,
"highlighted_in": "main_text"
},
{
"highlight": "In contrast, the Trefis High Quality Portfolio, with a collection of 30 stocks, has outperformed the <em>S</em>&<em>P</em> <em>500</em> each year over the same period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.",
"sentiment": 0.2648,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "32766fe5-700c-465a-8482-00632e2c08ca",
"title": "US homebuilder NVR tops profit estimates as tight housing supply spurs sales By Reuters",
"description": "US homebuilder NVR tops profit estimates as tight housing supply spurs sales",
"keywords": "",
"snippet": "(Reuters) - U.S. homebuilder NVR (NYSE: ) Inc beat Wall Street estimates for first-quarter profit as tight housing supply drove demand for new homes.\n\nWith the ...",
"url": "https://www.investing.com/news/stock-market-news/us-homebuilder-nvr-tops-profit-estimates-as-tight-housing-supply-spurs-sales-3391186",
"image_url": "https://i-invdn-com.investing.com/news/LYNXNPEB7Q0U9_L.jpg",
"language": "en",
"published_at": "2024-04-23T14:26:35.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "NVR",
"name": "NVR, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 40.053844,
"sentiment_score": 0.3044,
"highlights": [
{
"highlight": "(Reuters) - U.S. homebuilder <em>NVR</em> (NYSE: ) Inc beat Wall Street estimates for first-quarter profit as tight housing supply drove demand for new homes.\n\nWith the popular 30-year fixed mortgage at around 7%, a majority of U.S. homeowners have deferred reselling their homes as they remain locked in mortgages below 5%.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "<em>NVR</em> posted first-quarter consolidated revenue of $2.33 billion beating analysts' estimates of $2.22 billion, according to LSEG data.\n\nNew orders for the company, which operates in 15 U.S. states, rose 3% to 6,049 homes. The average selling price per home rose 3% to $454,300.",
"sentiment": -0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "US homebuilder <em>NVR</em> tops profit estimates as tight housing supply spurs sales By Reuters",
"sentiment": 0.7351,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "89b32bfb-790e-409e-af84-0c5fd6bea6dc",
"title": "Walmart-backed fintech One launches 'buy now, pay later' loans, CNBC reports By Reuters",
"description": "Walmart-backed fintech One launches 'buy now, pay later' loans, CNBC reports",
"keywords": "",
"snippet": "(Reuters) - Walmart’s majority-owned fintech startup One has started offering buy now, pay later (BNPL) loans for big-ticket items like electronics and power ...",
"url": "https://www.investing.com/news/stock-market-news/walmartbacked-fintech-one-launches-buy-now-pay-later-loans-cnbc-reports-3391185",
"image_url": "https://i-invdn-com.investing.com/news/LYNXNPEA9E0ZA_L.jpg",
"language": "en",
"published_at": "2024-04-23T14:26:02.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "WMT",
"name": "Walmart Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 30.152143,
"sentiment_score": 0.2714,
"highlights": [
{
"highlight": "One will be going head-to-head with some of <em>Walmart</em> (NYSE: )'s existing BNPL partners like Affirm, who helped the retail giant generate $648 billion in revenue last year, the report said.\n\nAds for both One and Affirm are vying for consumer attention in the retail chain's electronics aisles, CNBC said in the report, citing a recent visit.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "BNPL providers like Affirm and One partner with retailers like Amazon.com (NASDAQ: ) and <em>Walmart</em> to finance customer purchases, earning a commission on the sale and interest on the loan.\n\nAffirm has also stepped outside the competitive e-commerce market, offering BNPL services for elective medical procedures.",
"sentiment": 0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "One and <em>Walmart</em> were not immediately available to comment.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Walmart</em>-backed fintech One launches 'buy now, pay later' loans, CNBC reports By Reuters",
"sentiment": -0.1027,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "d1f7cb8d-6038-4e7f-b9f9-32e7d45f051e",
"title": "Buy now, pay later lender Affirm pushes into elective medical procedures By Reuters",
"description": "Buy now, pay later lender Affirm pushes into elective medical procedures",
"keywords": "",
"snippet": "By Hannah Lang\n\n(Reuters) - Fintech lender Affirm has started quietly offering \"buy now, pay later\" (BNPL) loans for elective medical procedures, in a major pus...",
"url": "https://www.investing.com/news/economy/buy-now-pay-later-lender-affirm-pushes-into-elective-medical-procedures-3390330",
"image_url": "https://i-invdn-com.investing.com/news/LYNXMPED2F1S6_L.jpg",
"language": "en",
"published_at": "2024-04-23T10:24:14.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "AMZN",
"name": "Amazon.com, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 10.496549,
"sentiment_score": 0.6705,
"highlights": [
{
"highlight": "BNPL providers partner with retailers like <em>Amazon.com</em> (NASDAQ: ) and Walmart (NYSE: ) to finance customer purchases, earning a commission on the sale and interest on the loan, which shoppers repay in a handful of installments. BNPL loans drove $75 billion in online spending in 2023, up 14.3% from 2022, according to Adobe (NASDAQ: ) Analytics.",
"sentiment": 0.6705,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "SYF",
"name": "Synchrony Financial",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 25.147587,
"sentiment_score": 0.9153,
"highlights": [
{
"highlight": "Affirm is marketing elective medical procedure loans as an alternative to medical credit cards, like <em>Synchrony</em> <em>Financial</em> (NYSE: )'s CareCredit, and installment loans. Those products typically waive interest payments for a promotional period after which annual interest is on average 27%, according to the CFPB.\n\nhere or remove ads . 3rd party Ad.",
"sentiment": 0.9153,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "WMT",
"name": "Walmart Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 10.747253,
"sentiment_score": 0.6705,
"highlights": [
{
"highlight": "BNPL providers partner with retailers like Amazon.com (NASDAQ: ) and <em>Walmart</em> (NYSE: ) to finance customer purchases, earning a commission on the sale and interest on the loan, which shoppers repay in a handful of installments. BNPL loans drove $75 billion in online spending in 2023, up 14.3% from 2022, according to Adobe (NASDAQ: ) Analytics.",
"sentiment": 0.6705,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "S1YF34.SA",
"name": "Synchrony Financial",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Financial Services",
"match_score": 20.101067,
"sentiment_score": 0.9153,
"highlights": [
{
"highlight": "Affirm is marketing elective medical procedure loans as an alternative to medical credit cards, like <em>Synchrony</em> <em>Financial</em> (NYSE: )'s CareCredit, and installment loans. Those products typically waive interest payments for a promotional period after which annual interest is on average 27%, according to the CFPB.\n\nhere or remove ads . 3rd party Ad.",
"sentiment": 0.9153,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "3ee9baa9-f05e-4315-bedf-f61939631073",
"title": "Wall Street gains on bright earnings, megacaps' support",
"description": "Wall Street's main indexes rose on Tuesday as some growth and chip shares gained, while stocks like General Motors and Spotify advanced on upbeat earnings updates ahead of quarterly reports from big technology companies.",
"keywords": "",
"snippet": "(April 23): Wall Street's main indexes rose on Tuesday as some growth and chip shares gained, while stocks like General Motors and Spotify advanced on upbeat ea...",
"url": "https://theedgemalaysia.com/node/709090",
"image_url": "https://assets.theedgemarkets.com/387312040-Wall-St-NYSE-building-New-York-Stock-Exchg-px-MichaelNagle-svd-Mon16052022_20230401110809_bloomberg_15.jpg",
"language": "en",
"published_at": "2024-04-23T14:19:22.000000Z",
"source": "theedgemarkets.com",
"relevance_score": null,
"entities": [
{
"symbol": "GM",
"name": "General Motors Company",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 17.717283,
"sentiment_score": 0.69935,
"highlights": [
{
"highlight": "(April 23): Wall Street's main indexes rose on Tuesday as some growth and chip shares gained, while stocks like <em>General</em> <em>Motors</em> and Spotify advanced on upbeat earnings updates ahead of quarterly reports from big technology companies.",
"sentiment": 0.872,
"highlighted_in": "main_text"
},
{
"highlight": "On the earnings front, <em>General</em> <em>Motors</em> advanced 4.8% after the automaker posted quarterly results above Wall Street targets and raised its annual forecast.\n\nSpotify gained 12.4% after the Swedish music streaming company's quarterly gross profit topped €1 billion (RM5.2 billion) for the first time.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "DHR",
"name": "Danaher Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.253548,
"sentiment_score": 0.8176,
"highlights": [
{
"highlight": "<em>Danaher</em> jumped 6.6% after the life sciences firm beat quarterly profit and sales expectations.\n\n\"Overall, people are happy with how (earnings) have gone because mostly they're surprised that things aren't worse,\" said Will McDonough, chairman and CEO of Corestone Capital.",
"sentiment": 0.8176,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NUE",
"name": "Nucor Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Basic Materials",
"match_score": 15.106237,
"sentiment_score": 0.34,
"highlights": [
{
"highlight": "Among other stocks, <em>Nucor</em> Corp shed 6.0% as the steelmaker missed Wall Street estimates for first-quarter earnings.\n\nRoblox added 4.1% after JPMorgan upgraded the gaming platform to \"overweight\" from \"neutral\" on significant monetization opportunity.",
"sentiment": 0.34,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "SPGI",
"name": "S&P Global Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 14.886436,
"sentiment_score": 0,
"highlights": [
{
"highlight": "On the data front, a preliminary reading of the April <em>S</em>&<em>P</em> <em>Global</em> Composite PMI Output Index, which tracks the manufacturing and services sectors, came in at 50.9.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RBLX",
"name": "Roblox Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 13.36722,
"sentiment_score": 0.5574,
"highlights": [
{
"highlight": "<em>Roblox</em> added 4.1% after JPMorgan upgraded the gaming platform to \"overweight\" from \"neutral\" on significant monetization opportunity.\n\nHibbett jumped 18.4% as JD Sports Fashion proposed to buy the athletic fashion retailer for about US$1.08 billion.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "02511fe1-4523-4b37-9ce4-cd4ee46e35c7",
"title": "Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern? (NASDAQ:GILD)",
"description": "Gilead Sciences will report its Q1 2024 earnings on Thursday, April 25. Check out whether GILD stock is a good buy ahead of Q1 earnings.",
"keywords": "",
"snippet": "Matthew J Thomas/iStock via Getty Images\n\nGilead Sciences Overview\n\nIt's been quite a while since I first covered what I termed the ugly duckling of Big Pharma,...",
"url": "https://seekingalpha.com/article/4685264-gilead-q1-earnings-preview-most-gains-wiped-out-cause-for-concern",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1319956561/image_1319956561.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2024-04-23T13:00:03.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "NONOF",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.074333,
"sentiment_score": 0.1263,
"highlights": [
{
"highlight": "However, GILD stock has since given back most of its gains, largely due to sector-wide underperformance (with the exception of GLP-1 receptor agonist plays Eli Lilly and Company, LLY, and <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em>, NVO) in general and disappointing data from the EVOKE-01 Phase 3 trial in January in particular.",
"sentiment": 0.1263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BRM.DE",
"name": "Bristol-Myers Squibb Company",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 19.073978,
"sentiment_score": 0,
"highlights": [
{
"highlight": "MRK), Trulicity (Eli Lilly & Company, LLY), and Opdivo (<em>Bristol</em>-<em>Myers</em> <em>Squibb</em> <em>Company</em>, BMY). Other drugs likely to be negotiated are Epclusa in 2027 (less than 4% of product sales in 2023) and Genvoya in 2028 (sales contribution in 2023 of less than 6%, LOE in the U.S. in 2029).",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GIS.DE",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.254593,
"sentiment_score": 0.2045,
"highlights": [
{
"highlight": "Matthew J Thomas/iStock via Getty Images\n\n<em>Gilead</em> <em>Sciences</em> Overview\n\nIt's been quite a while since I first covered what I termed the ugly duckling of Big Pharma, <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (NASDAQ:GILD). My last article was published in October 2022, when the stock got some love from Mr.",
"sentiment": 0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "Therefore, and because <em>Gilead</em> <em>Sciences</em> will report its first-quarter 2024 earnings on Thursday, April 25, after the market closes, I think it's a good time to take a fresh look at the company.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 1: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Adjusted earnings per share surprise (own work, based on data from Seeking Alpha)\n\nOn average over the last 16 years, Gilead's reported earnings were broadly in line with estimates (-0.4% on average).",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 2: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Veklury sales between 2020 and 2023 (own work, based on company filings)\n\nWith Veklury sales now representing a smaller and smaller portion of Gilead's product sales (8.1% in 2023), one could argue that the company has a higher chance of meeting (or beating) estimates.",
"sentiment": -0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 3: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Table 1: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Sales, year-over-year sales growth/decline, U.S. sales, and expected LOE of selected treatments (own work, based on company filings) Figure 4: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 5: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Three-year average gross margin comparison with peers (own work, based on company filings)\n\nA fresh look at Gilead's - pre-CymaBay acquisition - balance sheet gave no cause for concern.",
"sentiment": -0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 6: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Debt maturity profile as of December 31, 2023 (own work, based on company filings)\n\nConclusion - Is GILD Stock A Buy, Sell Or Hold Now At $67?\n\nIt is of course disappointing to realize that Gilead stock has given back a large part of its gains since its - in my opinion justified - rise at the end of 2022.",
"sentiment": -0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "Table 2: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Valuation metrics (Seeking Alpha)\n\nOf course, valuing pharma companies can be tricky, but in the case of Gilead, I think it is reasonable to expect at least a continuation of the current free cash flow stream.",
"sentiment": 0.705,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 7: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Discounted cash flow sensitivity analysis (own work, based on company filings)\n\nThank you very much for reading my latest article. Whether you agree or disagree with my conclusions, I always welcome your opinion and feedback in the comments below.",
"sentiment": 0.6808,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NOVC.DE",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.074348,
"sentiment_score": 0.1263,
"highlights": [
{
"highlight": "However, GILD stock has since given back most of its gains, largely due to sector-wide underperformance (with the exception of GLP-1 receptor agonist plays Eli Lilly and Company, LLY, and <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em>, NVO) in general and disappointing data from the EVOKE-01 Phase 3 trial in January in particular.",
"sentiment": 0.1263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "6MK.DE",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.884804,
"sentiment_score": 0,
"highlights": [
{
"highlight": "According to this article, Biktarvy is listed as a major drug likely to be negotiated in 2028, after Keytruda (<em>Merck</em> & <em>Co</em>, <em>Inc</em>. MRK), Trulicity (Eli Lilly & Company, LLY), and Opdivo (Bristol-Myers Squibb Company, BMY).",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LLY.DE",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.998838,
"sentiment_score": 0.1263,
"highlights": [
{
"highlight": "However, GILD stock has since given back most of its gains, largely due to sector-wide underperformance (with the exception of GLP-1 receptor agonist plays <em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em>, LLY, and Novo Nordisk A/S, NVO) in general and disappointing data from the EVOKE-01 Phase 3 trial in January in particular.",
"sentiment": 0.1263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NOVA.DE",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.074162,
"sentiment_score": 0.1263,
"highlights": [
{
"highlight": "However, GILD stock has since given back most of its gains, largely due to sector-wide underperformance (with the exception of GLP-1 receptor agonist plays Eli Lilly and Company, LLY, and <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em>, NVO) in general and disappointing data from the EVOKE-01 Phase 3 trial in January in particular.",
"sentiment": 0.1263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK.PA",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "fr",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.884656,
"sentiment_score": 0,
"highlights": [
{
"highlight": "According to this article, Biktarvy is listed as a major drug likely to be negotiated in 2028, after Keytruda (<em>Merck</em> & <em>Co</em>, <em>Inc</em>. MRK), Trulicity (Eli Lilly & Company, LLY), and Opdivo (Bristol-Myers Squibb Company, BMY).",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NVON.MX",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.074291,
"sentiment_score": 0.1263,
"highlights": [
{
"highlight": "However, GILD stock has since given back most of its gains, largely due to sector-wide underperformance (with the exception of GLP-1 receptor agonist plays Eli Lilly and Company, LLY, and <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em>, NVO) in general and disappointing data from the EVOKE-01 Phase 3 trial in January in particular.",
"sentiment": 0.1263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BMY.MX",
"name": "Bristol-Myers Squibb Company",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 19.072094,
"sentiment_score": 0,
"highlights": [
{
"highlight": "MRK), Trulicity (Eli Lilly & Company, LLY), and Opdivo (<em>Bristol</em>-<em>Myers</em> <em>Squibb</em> <em>Company</em>, BMY). Other drugs likely to be negotiated are Epclusa in 2027 (less than 4% of product sales in 2023) and Genvoya in 2028 (sales contribution in 2023 of less than 6%, LOE in the U.S. in 2029).",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILD.MX",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.25213,
"sentiment_score": 0.2045,
"highlights": [
{
"highlight": "Matthew J Thomas/iStock via Getty Images\n\n<em>Gilead</em> <em>Sciences</em> Overview\n\nIt's been quite a while since I first covered what I termed the ugly duckling of Big Pharma, <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (NASDAQ:GILD). My last article was published in October 2022, when the stock got some love from Mr.",
"sentiment": 0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "Therefore, and because <em>Gilead</em> <em>Sciences</em> will report its first-quarter 2024 earnings on Thursday, April 25, after the market closes, I think it's a good time to take a fresh look at the company.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 1: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Adjusted earnings per share surprise (own work, based on data from Seeking Alpha)\n\nOn average over the last 16 years, Gilead's reported earnings were broadly in line with estimates (-0.4% on average).",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 2: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Veklury sales between 2020 and 2023 (own work, based on company filings)\n\nWith Veklury sales now representing a smaller and smaller portion of Gilead's product sales (8.1% in 2023), one could argue that the company has a higher chance of meeting (or beating) estimates.",
"sentiment": -0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 3: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Table 1: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Sales, year-over-year sales growth/decline, U.S. sales, and expected LOE of selected treatments (own work, based on company filings) Figure 4: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 5: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Three-year average gross margin comparison with peers (own work, based on company filings)\n\nA fresh look at Gilead's - pre-CymaBay acquisition - balance sheet gave no cause for concern.",
"sentiment": -0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 6: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Debt maturity profile as of December 31, 2023 (own work, based on company filings)\n\nConclusion - Is GILD Stock A Buy, Sell Or Hold Now At $67?\n\nIt is of course disappointing to realize that Gilead stock has given back a large part of its gains since its - in my opinion justified - rise at the end of 2022.",
"sentiment": -0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "Table 2: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Valuation metrics (Seeking Alpha)\n\nOf course, valuing pharma companies can be tricky, but in the case of Gilead, I think it is reasonable to expect at least a continuation of the current free cash flow stream.",
"sentiment": 0.705,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 7: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Discounted cash flow sensitivity analysis (own work, based on company filings)\n\nThank you very much for reading my latest article. Whether you agree or disagree with my conclusions, I always welcome your opinion and feedback in the comments below.",
"sentiment": 0.6808,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK.MX",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.884531,
"sentiment_score": 0,
"highlights": [
{
"highlight": "According to this article, Biktarvy is listed as a major drug likely to be negotiated in 2028, after Keytruda (<em>Merck</em> & <em>Co</em>, <em>Inc</em>. MRK), Trulicity (Eli Lilly & Company, LLY), and Opdivo (Bristol-Myers Squibb Company, BMY).",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LLY.MX",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.997904,
"sentiment_score": 0.1263,
"highlights": [
{
"highlight": "However, GILD stock has since given back most of its gains, largely due to sector-wide underperformance (with the exception of GLP-1 receptor agonist plays <em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em>, LLY, and Novo Nordisk A/S, NVO) in general and disappointing data from the EVOKE-01 Phase 3 trial in January in particular.",
"sentiment": 0.1263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NOVOBN.MX",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "N/A",
"match_score": 13.074242,
"sentiment_score": 0.1263,
"highlights": [
{
"highlight": "However, GILD stock has since given back most of its gains, largely due to sector-wide underperformance (with the exception of GLP-1 receptor agonist plays Eli Lilly and Company, LLY, and <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em>, NVO) in general and disappointing data from the EVOKE-01 Phase 3 trial in January in particular.",
"sentiment": 0.1263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CBAY",
"name": "CymaBay Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 15.843098,
"sentiment_score": 0,
"highlights": [
{
"highlight": "However, this segment will grow inorganically in the future as Gilead recently completed the acquisition of <em>CymaBay</em> <em>Therapeutics</em>, <em>Inc</em>. (CBAY), which adds seladelpar to the portfolio. The drug has shown the best-in-disease profile in its Phase 3 study as a second-line treatment for primary biliary cholangitis (PBC).",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0TDD.L",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 13.074165,
"sentiment_score": 0.1263,
"highlights": [
{
"highlight": "However, GILD stock has since given back most of its gains, largely due to sector-wide underperformance (with the exception of GLP-1 receptor agonist plays Eli Lilly and Company, LLY, and <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em>, NVO) in general and disappointing data from the EVOKE-01 Phase 3 trial in January in particular.",
"sentiment": 0.1263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 85.76043,
"sentiment_score": 0.185909,
"highlights": [
{
"highlight": "Matthew J Thomas/iStock via Getty Images\n\n<em>Gilead</em> <em>Sciences</em> Overview\n\nIt's been quite a while since I first covered what I termed the ugly duckling of Big Pharma, <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (<em>NASDAQ:GILD</em>). My last article was published in October 2022, when the stock got some love from Mr.",
"sentiment": 0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "Therefore, and because <em>Gilead</em> <em>Sciences</em> will report its first-quarter 2024 earnings on Thursday, April 25, after the market closes, I think it's a good time to take a fresh look at the company.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 1: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Adjusted earnings per share surprise (own work, based on data from Seeking Alpha)\n\nOn average over the last 16 years, Gilead's reported earnings were broadly in line with estimates (-0.4% on average).",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 2: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Veklury sales between 2020 and 2023 (own work, based on company filings)\n\nWith Veklury sales now representing a smaller and smaller portion of Gilead's product sales (8.1% in 2023), one could argue that the company has a higher chance of meeting (or beating) estimates.",
"sentiment": -0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 3: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Table 1: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Sales, year-over-year sales growth/decline, U.S. sales, and expected LOE of selected treatments (own work, based on company filings) Figure 4: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 5: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Three-year average gross margin comparison with peers (own work, based on company filings)\n\nA fresh look at Gilead's - pre-CymaBay acquisition - balance sheet gave no cause for concern.",
"sentiment": -0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 6: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Debt maturity profile as of December 31, 2023 (own work, based on company filings)\n\nConclusion - Is GILD Stock A Buy, Sell Or Hold Now At $67?\n\nIt is of course disappointing to realize that Gilead stock has given back a large part of its gains since its - in my opinion justified - rise at the end of 2022.",
"sentiment": -0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "Table 2: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Valuation metrics (Seeking Alpha)\n\nOf course, valuing pharma companies can be tricky, but in the case of Gilead, I think it is reasonable to expect at least a continuation of the current free cash flow stream.",
"sentiment": 0.705,
"highlighted_in": "main_text"
},
{
"highlight": "Figure 7: <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>. (GILD): Discounted cash flow sensitivity analysis (own work, based on company filings)\n\nThank you very much for reading my latest article. Whether you agree or disagree with my conclusions, I always welcome your opinion and feedback in the comments below.",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ:GILD</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "LLY",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.997107,
"sentiment_score": 0.1263,
"highlights": [
{
"highlight": "However, GILD stock has since given back most of its gains, largely due to sector-wide underperformance (with the exception of GLP-1 receptor agonist plays <em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em>, LLY, and Novo Nordisk A/S, NVO) in general and disappointing data from the EVOKE-01 Phase 3 trial in January in particular.",
"sentiment": 0.1263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NVO",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.074055,
"sentiment_score": 0.1263,
"highlights": [
{
"highlight": "However, GILD stock has since given back most of its gains, largely due to sector-wide underperformance (with the exception of GLP-1 receptor agonist plays Eli Lilly and Company, LLY, and <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em>, NVO) in general and disappointing data from the EVOKE-01 Phase 3 trial in January in particular.",
"sentiment": 0.1263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BMY",
"name": "Bristol-Myers Squibb Company",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 19.068096,
"sentiment_score": 0,
"highlights": [
{
"highlight": "MRK), Trulicity (Eli Lilly & Company, LLY), and Opdivo (<em>Bristol</em>-<em>Myers</em> <em>Squibb</em> <em>Company</em>, BMY). Other drugs likely to be negotiated are Epclusa in 2027 (less than 4% of product sales in 2023) and Genvoya in 2028 (sales contribution in 2023 of less than 6%, LOE in the U.S. in 2029).",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.883935,
"sentiment_score": 0,
"highlights": [
{
"highlight": "According to this article, Biktarvy is listed as a major drug likely to be negotiated in 2028, after Keytruda (<em>Merck</em> & <em>Co</em>, <em>Inc</em>. MRK), Trulicity (Eli Lilly & Company, LLY), and Opdivo (Bristol-Myers Squibb Company, BMY).",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0I5P.L",
"name": "CymaBay Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 15.827686,
"sentiment_score": 0,
"highlights": [
{
"highlight": "However, this segment will grow inorganically in the future as Gilead recently completed the acquisition of <em>CymaBay</em> <em>Therapeutics</em>, <em>Inc</em>. (CBAY), which adds seladelpar to the portfolio. The drug has shown the best-in-disease profile in its Phase 3 study as a second-line treatment for primary biliary cholangitis (PBC).",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0Q1G.L",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 14.996292,
"sentiment_score": 0.1263,
"highlights": [
{
"highlight": "However, GILD stock has since given back most of its gains, largely due to sector-wide underperformance (with the exception of GLP-1 receptor agonist plays <em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em>, LLY, and Novo Nordisk A/S, NVO) in general and disappointing data from the EVOKE-01 Phase 3 trial in January in particular.",
"sentiment": 0.1263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BMYB34.SA",
"name": "Bristol-Myers Squibb Company",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 19.064415,
"sentiment_score": 0,
"highlights": [
{
"highlight": "MRK), Trulicity (Eli Lilly & Company, LLY), and Opdivo (<em>Bristol</em>-<em>Myers</em> <em>Squibb</em> <em>Company</em>, BMY). Other drugs likely to be negotiated are Epclusa in 2027 (less than 4% of product sales in 2023) and Genvoya in 2028 (sales contribution in 2023 of less than 6%, LOE in the U.S. in 2029).",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LILY34.SA",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.996115,
"sentiment_score": 0.1263,
"highlights": [
{
"highlight": "However, GILD stock has since given back most of its gains, largely due to sector-wide underperformance (with the exception of GLP-1 receptor agonist plays <em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em>, LLY, and Novo Nordisk A/S, NVO) in general and disappointing data from the EVOKE-01 Phase 3 trial in January in particular.",
"sentiment": 0.1263,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "e1c9b8e3-70a3-4ac5-83c7-0410db1e3de9",
"title": "Futures Pointing To Extended Rebound On Wall Street",
"description": "The major U.S. index futures are currently pointing to higher open on Tuesday, with stocks likely to extend the rebound seen in the previous session. Traders may continue to look to pick up stocks at relatively reduced levels amid a positive reaction to some of the latest corporate earnings news.",
"keywords": "stocks, wall street, market analysis, MMA",
"snippet": "The major U.S. index futures are currently pointing to higher open on Tuesday, with stocks likely to extend the rebound seen in the previous session.\n\nTraders m...",
"url": "https://www.rttnews.com/story.aspx?Id=3440802",
"image_url": "https://cdn.rttnews.com/images/v4/RTTNews-logo-512x512.png",
"language": "en",
"published_at": "2024-04-23T12:48:25.000000Z",
"source": "rttnews.com",
"relevance_score": null,
"entities": [
{
"symbol": "AAPL",
"name": "Apple Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 5.651653,
"sentiment_score": 0.1779,
"highlights": [
{
"highlight": "Asia\n\nAsian stocks turned in a mixed performance on Tuesday as investors watched the latest developments in the Middle East and looked forward to earnings results from U.S. titans including Amazon, <em>Apple</em>, Netflix and General Motors for directional cues.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AAL",
"name": "American Airlines Group Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 8.704706,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Citigroup, Delta Airlines, Seagate Technology, Moderna and <em>American</em> <em>Airlines</em> also ended sharply higher.\n\nVerizon ended 4.7 percent down. The company, which announced weak profit and slightly higher revenues in its first quarter, maintained its fiscal 2024 earnings outlook.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GOOGL",
"name": "Alphabet Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 10.946305,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Earnings season also starts to pick up steam this week, with Tesla (TSLA), Boeing (BA), IBM (IBM), Caterpillar (CAT), Honeywell (HON), <em>Alphabet</em> (<em>GOOGL</em>), Intel (INTC), Microsoft (MSFT), Chevron (CVX) and Exxon Mobil (XOM) among the companies due to report their quarterly results.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AMGN",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.149244,
"sentiment_score": 0.9168,
"highlights": [
{
"highlight": "Amazon, McDonald, Chevron, <em>Amgen</em> and Walmart gained 1 to 1.5 percent.\n\nSalesforce.com shares gained more than 1 percent after the company backed away from its talks to acquire data-management software firm Informatica.\n\nFord Motor rallied more than 6 percent. United Airlines Holdings gained about 5 percent. Nvidia climbed 4.35 percent.",
"sentiment": 0.9168,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NVDA",
"name": "NVIDIA Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 6.54529,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Nvidia</em> climbed 4.35 percent. Citigroup, Delta Airlines, Seagate Technology, Moderna and American Airlines also ended sharply higher.\n\nVerizon ended 4.7 percent down. The company, which announced weak profit and slightly higher revenues in its first quarter, maintained its fiscal 2024 earnings outlook.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MSFT",
"name": "Microsoft Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 5.837828,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Earnings season also starts to pick up steam this week, with Tesla (TSLA), Boeing (BA), IBM (IBM), Caterpillar (CAT), Honeywell (HON), Alphabet (GOOGL), Intel (INTC), <em>Microsoft</em> (MSFT), Chevron (CVX) and Exxon Mobil (XOM) among the companies due to report their quarterly results.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "UAL",
"name": "United Airlines Holdings, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 10.911894,
"sentiment_score": 0.3818,
"highlights": [
{
"highlight": "<em>United</em> <em>Airlines</em> <em>Holdings</em> gained about 5 percent. Nvidia climbed 4.35 percent. Citigroup, Delta Airlines, Seagate Technology, Moderna and American Airlines also ended sharply higher.\n\nVerizon ended 4.7 percent down.",
"sentiment": 0.3818,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TSLA",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 7.993784,
"sentiment_score": -0.418,
"highlights": [
{
"highlight": "Earnings season also starts to pick up steam this week, with <em>Tesla</em> (TSLA), Boeing (BA), IBM (IBM), Caterpillar (CAT), Honeywell (HON), Alphabet (GOOGL), Intel (INTC), Microsoft (MSFT), Chevron (CVX) and Exxon Mobil (XOM) among the companies due to report their quarterly results.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Tesla</em> drifted down 3.4 percent, on concerns over gross margins after the company lowered prices in several .\n\nCommodity, Currency Markets\n\nCrude oil futures are falling $0.72 to $81.18 a barrel. Meanwhile, gold futures are slumping $24.5 to $2,321.90 an ounce.",
"sentiment": -0.836,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 6.584343,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Citigroup, Delta Airlines, Seagate Technology, <em>Moderna</em> and American Airlines also ended sharply higher.\n\nVerizon ended 4.7 percent down. The company, which announced weak profit and slightly higher revenues in its first quarter, maintained its fiscal 2024 earnings outlook.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NFLX",
"name": "Netflix, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 6.077508,
"sentiment_score": 0.1779,
"highlights": [
{
"highlight": "Asia\n\nAsian stocks turned in a mixed performance on Tuesday as investors watched the latest developments in the Middle East and looked forward to earnings results from U.S. titans including Amazon, Apple, <em>Netflix</em> and General Motors for directional cues.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PEP",
"name": "PepsiCo, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 7.828838,
"sentiment_score": 0.431,
"highlights": [
{
"highlight": "Snack and beverage giant <em>PepsiCo</em> (PEP) is also likely to see initial strength after reporting better than expected first quarter results.\n\nOn the other hand, shares of JetBlue (JBLU) are seeing substantial pre-market weakness after the airline reported a narrower than expected first quarter loss but lowered its 2024 revenue forecast.",
"sentiment": 0.431,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "STX",
"name": "Seagate Technology plc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 10.534179,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Citigroup, Delta Airlines, <em>Seagate</em> <em>Technology</em>, Moderna and American Airlines also ended sharply higher.\n\nVerizon ended 4.7 percent down. The company, which announced weak profit and slightly higher revenues in its first quarter, maintained its fiscal 2024 earnings outlook.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NVS",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 12.946979,
"sentiment_score": 0.5574,
"highlights": [
{
"highlight": "Drug major <em>Novartis</em> <em>AG</em> surged 4.7 percent after raising its full-year guidance.\n\nJD Sports Fashion jumped more than 6 percent in London after it proposed to buy Hibbett in a deal that values the American sporting-goods retailer at $1.08 billion.\n\nMining giant Anglo American tumbled 3.5 percent after cutting its diamond production guidance.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NVSEF",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 12.94634,
"sentiment_score": 0.5574,
"highlights": [
{
"highlight": "Drug major <em>Novartis</em> <em>AG</em> surged 4.7 percent after raising its full-year guidance.\n\nJD Sports Fashion jumped more than 6 percent in London after it proposed to buy Hibbett in a deal that values the American sporting-goods retailer at $1.08 billion.\n\nMining giant Anglo American tumbled 3.5 percent after cutting its diamond production guidance.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RNLSY",
"name": "Renault SA",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 10.502877,
"sentiment_score": 0.5562,
"highlights": [
{
"highlight": "France's <em>Renault</em> <em>SA</em> fell about 1 percent as the auto major reported a marginal rise in revenue for the first quarter.\n\nSAP AG shares surged 3.5 percent. The German software maker reaffirmed its outlook for 2024 after Q! cloud revenue increased 24 percent to 3.93 billion euro.\n\nU.S.",
"sentiment": 0.5562,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RNSDF",
"name": "Renault SA",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 10.502877,
"sentiment_score": 0.5562,
"highlights": [
{
"highlight": "France's <em>Renault</em> <em>SA</em> fell about 1 percent as the auto major reported a marginal rise in revenue for the first quarter.\n\nSAP AG shares surged 3.5 percent. The German software maker reaffirmed its outlook for 2024 after Q! cloud revenue increased 24 percent to 3.93 billion euro.\n\nU.S.",
"sentiment": 0.5562,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RNL.DE",
"name": "Renault SA",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 10.502764,
"sentiment_score": 0.5562,
"highlights": [
{
"highlight": "France's <em>Renault</em> <em>SA</em> fell about 1 percent as the auto major reported a marginal rise in revenue for the first quarter.\n\nSAP AG shares surged 3.5 percent. The German software maker reaffirmed its outlook for 2024 after Q! cloud revenue increased 24 percent to 3.93 billion euro.\n\nU.S.",
"sentiment": 0.5562,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "^FCHI",
"name": "CAC 40",
"exchange": null,
"exchange_long": null,
"country": "fr",
"type": "index",
"industry": "N/A",
"match_score": 11.552645,
"sentiment_score": 0,
"highlights": [
{
"highlight": "While the German DAX Index is up by 0.9 percent, the French <em>CAC</em> <em>40</em> Index is up by 0.3 percent and the U.K.'s FTSE 100 Index is nearly unchanged.\n\nKuehne + Nagel International, a Swiss transport and logistics company, declined 2.6 percent after its first-quarter earnings fell 40 percent.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RNO.PA",
"name": "Renault SA",
"exchange": null,
"exchange_long": null,
"country": "fr",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 10.502626,
"sentiment_score": 0.5562,
"highlights": [
{
"highlight": "France's <em>Renault</em> <em>SA</em> fell about 1 percent as the auto major reported a marginal rise in revenue for the first quarter.\n\nSAP AG shares surged 3.5 percent. The German software maker reaffirmed its outlook for 2024 after Q! cloud revenue increased 24 percent to 3.93 billion euro.\n\nU.S.",
"sentiment": 0.5562,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NVSN.MX",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 12.941173,
"sentiment_score": 0.5574,
"highlights": [
{
"highlight": "Drug major <em>Novartis</em> <em>AG</em> surged 4.7 percent after raising its full-year guidance.\n\nJD Sports Fashion jumped more than 6 percent in London after it proposed to buy Hibbett in a deal that values the American sporting-goods retailer at $1.08 billion.\n\nMining giant Anglo American tumbled 3.5 percent after cutting its diamond production guidance.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "^GSPC",
"name": "S&P 500",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "index",
"industry": "N/A",
"match_score": 12.1105,
"sentiment_score": 0.4215,
"highlights": [
{
"highlight": "The <em>S</em>&<em>P</em> <em>500</em>, which climbed to a high of 5,038.84, settled at 5,010.60, gaining 43.37 points or 0.9 percent, while the Nasdaq ended higher by 169.30 points or 1.1 percent at 15,451.31, off the day's high of 15,539.00.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0K9E.L",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 12.939217,
"sentiment_score": 0.5574,
"highlights": [
{
"highlight": "Drug major <em>Novartis</em> <em>AG</em> surged 4.7 percent after raising its full-year guidance.\n\nJD Sports Fashion jumped more than 6 percent in London after it proposed to buy Hibbett in a deal that values the American sporting-goods retailer at $1.08 billion.\n\nMining giant Anglo American tumbled 3.5 percent after cutting its diamond production guidance.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BXB.AX",
"name": "Brambles Limited",
"exchange": null,
"exchange_long": null,
"country": "au",
"type": "equity",
"industry": "Industrials",
"match_score": 10.971927,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Logistics firm <em>Brambles</em> plunged 6.3 percent after posting a fall in third-quarter group volumes.\n\nEurope\n\nEuropean stocks have moved higher on Tuesday after a survey showed that activity in the euro zone expanded at its fastest pace in nearly a year this month.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "WBC.AX",
"name": "Westpac Banking Corporation",
"exchange": null,
"exchange_long": null,
"country": "au",
"type": "equity",
"industry": "Financial Services",
"match_score": 12.437015,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Westpac</em> <em>Banking</em> Corp gained 0.9 percent despite flagging a hit to its half-year earnings. Gold miners slid the most, with Northern Star Resources losing 3.5 percent and Regis Resources tumbling 4.6 percent.\n\nLogistics firm Brambles plunged 6.3 percent after posting a fall in third-quarter group volumes.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NST.AX",
"name": "Northern Star Resources Limited",
"exchange": null,
"exchange_long": null,
"country": "au",
"type": "equity",
"industry": "Basic Materials",
"match_score": 12.14042,
"sentiment_score": -0.3818,
"highlights": [
{
"highlight": "Gold miners slid the most, with <em>Northern</em> <em>Star</em> <em>Resources</em> losing 3.5 percent and Regis Resources tumbling 4.6 percent.\n\nLogistics firm Brambles plunged 6.3 percent after posting a fall in third-quarter group volumes.",
"sentiment": -0.3818,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RRL.AX",
"name": "Regis Resources Limited",
"exchange": null,
"exchange_long": null,
"country": "au",
"type": "equity",
"industry": "Basic Materials",
"match_score": 12.045558,
"sentiment_score": -0.3818,
"highlights": [
{
"highlight": "Gold miners slid the most, with Northern Star Resources losing 3.5 percent and <em>Regis</em> <em>Resources</em> tumbling 4.6 percent.\n\nLogistics firm Brambles plunged 6.3 percent after posting a fall in third-quarter group volumes.",
"sentiment": -0.3818,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "^AXJO",
"name": "S&P/ASX 200",
"exchange": null,
"exchange_long": null,
"country": "au",
"type": "index",
"industry": "N/A",
"match_score": 23.36822,
"sentiment_score": 0,
"highlights": [
{
"highlight": "The benchmark <em>S</em>&<em>P</em> <em>ASX</em> <em>200</em> Index rose 0.5 percent to 7,683.50, while the broader All Ordinaries Index settled 0.5 percent higher at 7,937.90.\n\nWestpac Banking Corp gained 0.9 percent despite flagging a hit to its half-year earnings. Gold miners slid the most, with Northern Star Resources losing 3.5 percent and Regis Resources tumbling 4.6 percent.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "^HSI",
"name": "HANG SENG INDEX",
"exchange": null,
"exchange_long": null,
"country": "hk",
"type": "index",
"industry": "N/A",
"match_score": 20.372036,
"sentiment_score": 0.296,
"highlights": [
{
"highlight": "The benchmark Shanghai Composite Index dropped 0.7 percent to 3,021.98, while Hong Kong's <em>Hang</em> <em>Seng</em> <em>index</em> rallied 1.9 percent to 16,828.93 after a pledge by China's securities regulator to bolster the market.",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NOVN.SW",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "ch",
"type": "equity",
"industry": "Healthcare",
"match_score": 12.937533,
"sentiment_score": 0.5574,
"highlights": [
{
"highlight": "Drug major <em>Novartis</em> <em>AG</em> surged 4.7 percent after raising its full-year guidance.\n\nJD Sports Fashion jumped more than 6 percent in London after it proposed to buy Hibbett in a deal that values the American sporting-goods retailer at $1.08 billion.\n\nMining giant Anglo American tumbled 3.5 percent after cutting its diamond production guidance.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "aa19909d-59e0-44ec-96f5-492947ca3e6a",
"title": "Wall Street Breakfast: Brace For Impact",
"description": "This article discusses Tesla's upcoming earnings, UnitedHealth confirming personal data hit by hack, China still buying advanced Nvidia chips, and NYSE polling interest in 24/7 stock trade.",
"keywords": "",
"snippet": "Brace for impact\n\nSlowing demand... Intense competition... Price cuts... Layoffs... Tesla (TSLA) has had it rough in the recent past, and shareholders are now p...",
"url": "https://seekingalpha.com/article/4685221-wall-street-breakfast-brace-for-impact",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1338745823/image_1338745823.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2024-04-23T11:30:00.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "DELL",
"name": "Dell Technologies Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 14.287487,
"sentiment_score": 0.8074,
"highlights": [
{
"highlight": "These advanced chips were embedded in server products made by Super Micro Computer (SMCI) and <em>Dell</em> <em>Technologies</em> (DELL), according to tenders fulfilled between November 20 and February 28. This was after the U.S. had widened chip export controls, although it's unclear if the chips had been acquired prior to this.",
"sentiment": 0.8074,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ICE",
"name": "Intercontinental Exchange, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 13.611866,
"sentiment_score": 0.4588,
"highlights": [
{
"highlight": "The New York Stock Exchange, owned by <em>Intercontinental</em> <em>Exchange</em> (ICE) has started polling market participants on their interest in and potential implications of an exchange that trades stocks 24/7.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MSCL.SN",
"name": "MORGAN STANLEY",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 17.455692,
"sentiment_score": 0.3612,
"highlights": [
{
"highlight": "While Musk is likely to talk up the potential of the robotaxi business, <em>Morgan</em> <em>Stanley</em> warned investors to keep their hopes down. \"The event should offer some important clues as to how Tesla approaches autonomy (gen AI, non-rules based) and why the company is seemingly rapidly stockpiling its computational horsepower.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "^GSPC",
"name": "S&P 500",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "index",
"industry": "N/A",
"match_score": 16.715021,
"sentiment_score": -0.886,
"highlights": [
{
"highlight": "To note, Tesla's (TSLA) stock has slid around 43% so far this year, and is among the worst performers in the <em>S</em>&<em>P</em> <em>500</em> (SP500).\n\n\n\nSA commentary: SA analyst ValueAnalyst doesn't think it's all doom and gloom for Tesla investors, although they are staying on the sidelines for now.",
"sentiment": -0.886,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "ba338236-9c8a-4443-9af4-a350ab7324fd",
"title": "What’s a new Taylor Swift album worth?",
"description": "To her record label, not that much. For our SEO, quite a lot",
"keywords": "",
"snippet": "Print this page\n\nMany readers have told us that the ideal number of stories about Taylor Swift in the financial media is zero. Those people are not having a goo...",
"url": "https://www.ft.com/content/5d309b5d-936b-421a-b562-76a5e55499d2",
"image_url": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fwww.ft.com%2F__origami%2Fservice%2Fimage%2Fv2%2Fimages%2Fraw%2Fhttps%253A%252F%252Fd1e00ek4ebabms.cloudfront.net%252Fproduction%252F3deb930b-8db1-45be-8cb1-4adf4c3819a5.jpg%3Fsource%3Dnext-article%26fit%3Dscale-down%26quality%3Dhighest%26width%3D700%26dpr%3D1?source=next-opengraph&fit=scale-down&width=900",
"language": "en",
"published_at": "2024-04-23T14:18:48.000000Z",
"source": "ft.com",
"relevance_score": null,
"entities": [
{
"symbol": "SONY",
"name": "Sony Group Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 8.855268,
"sentiment_score": 0.91,
"highlights": [
{
"highlight": "The combined market share of UMG, <em>Sony</em> and Warner is more than 70 per cent.\n\nAny time you’ve heard a song while shopping or watching trash TV, there’s a better than one-in-three chance that it’s a UMG asset. Market share chart from Barclays:\n\nAnd Swift is probably worth less per sale to UMG than its average artist.",
"sentiment": 0.91,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "9409e3f2-02c6-42c6-ae6c-7dbf6e2cc70d",
"title": "3 series que Netflix arrancó de su catálogo y dejaron a suscriptores desolados",
"description": "Netflix es una de las plataformas más importantes de los últimos años, todo lo que buscas para ver o volver a repasar, seguramente lo vas a encontrar aquí. En",
"keywords": "",
"snippet": "Netflix es una de las plataformas más importantes de los últimos años, todo lo que buscas para ver o volver a repasar, seguramente lo vas a encontrar aquí. ...",
"url": "https://www.merca2.es/2024/04/23/netflix-catalogo-suscriptores-1650353/",
"image_url": "https://www.merca2.es/wp-content/uploads/2024/04/netflix-series-arranco-catalogo-1.jpg",
"language": "es",
"published_at": "2024-04-23T14:14:12.000000Z",
"source": "merca2.es",
"relevance_score": null,
"entities": [
{
"symbol": "SONY",
"name": "Sony Group Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 11.226522,
"sentiment_score": null,
"highlights": [
{
"highlight": "Pero, el que siempre funcionó fue Spider-Man, tanto con su serie animada de los 90 como con El espectacular Spider-Man del 2008; esta historia del trepa muros fue un lavado de cara dentro de la animación y cosechó muchos fans, lamentablemente, por cuestiones de derechos con <em>Sony</em>, las aventuras de Parker abandonaron la plataforma de «la gran N».",
"sentiment": -0.7579,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "NYSE",
"total_documents": 1446,
"sentiment_avg": 0.2644364364009995
}
]
}
Other details
Country
- us
- 4,171